In another study examining hepcidin, SF, and CRP levels in NDD-CKD patients, roxadustat treatment yielded a 16.9% reduction in hepcidin levels, a 30.9% reduction in SF levels, and a 15.3% increase in total iron-binding capacity (TIBC) compared with the control group [59]. The gene discussed is HAMP; the disease is Neurodevelopmental delay.